Core Viewpoint - The AI-driven drug development platform, DeepMind, has successfully completed a nearly $50 million Series D financing round, indicating strong investor confidence in the company's potential and growth prospects [1][1]. Financing Details - The Series D financing round was led by Dinghui Baifu, with participation from existing investors including New Ding Capital and Sequoia China [1][1]. - The financial advisory for this round was provided exclusively by Index Capital [1][1].